je.st
news
Tag: with
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
2017-01-09 14:00:47| Merck.com - Product News
Dateline City: WILMINGTON, D.E. & KENILWORTH, N.J. Additional pivotal studies evaluating Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, D.E. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incytes investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Language: English read more
Tags: with
development
program
combination
European Medicines Agencys CHMP Recommends Mercks KEYTRUDA (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...
2016-12-16 13:26:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tu Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
IAEG to launch 6 projects to find alternatives to technologies with hazardous chemistries in aerospace
2016-12-06 16:55:25| Green Car Congress
Tags: with
find
projects
technologies
Honda to show EV concept with AI emotion engine from joint project with Softbank
2016-12-06 13:55:22| Green Car Congress
Tags: with
show
project
engine
Brexit: Theresa May 'ambitious' over deal with EU
2016-12-06 09:51:43| BBC News | Business | UK Edition
Theresa May says she is "ambitious" about the deal the UK will strike when leaving the EU.
Tags: with
deal
ambitious
theresa
Sites : [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] next »